Moderna Inc (NASDAQ:MRNA) shares are trading higher Tuesday after the company announced two new vaccine candidate developments.
Moderna will launch a respiratory combination vaccine program to target three of the most significant viruses causing respiratory disease in older adults. The new combination respiratory vaccine candidate, mRNA-1230, would act as an annual booster targeting SARS-CoV-2 virus, influenza virus and respiratory syncytial virus.
Moderna also introduced a program to develop vaccine candidate mRNA-1287 against endemic human coronaviruses. Four human coronaviruses are endemic globally, accounting for approximately 10% to 30% of upper respiratory tract infections in adults.
See Also: Why Society Pass Shares Are Surging
MRNA 52-Week Range: $117.34 - $497.49
Moderna Shares were up 5.78% at $185.49 at time of publication.
Photo: mufidpwt from Pixabay.
